Addiction Medicine Journal Club: The Patient Experience of Depot versus Sublingual Buprenorphine - Audio Episode 2

INSTRUCTIONS - Start Here

Addiction Medicine Journal Club, Episode 2
The Patient Experience of Depot versus Sublingual Buprenorphine

Addiction is a disease that can be treated, and this audio will help you stay up to date with the latest research that you can use in your addiction medicine practice. In this episode of Addiction Medicine Journal Club, we discuss "Patient-Reported Outcomes of Treatment of Opioid Dependence with Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine."

Citation: Patient-Reported Outcomes of Treatment of Opioid Dependence with Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine. (The DEBUT trial) Nicholas Lintzeris; Et Al. JAMA Network Open, 10 May 2021, 2021:4(5):e219041. 

Available at https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779751

In our introduction, we discuss safe drug consumption sites. Take a look at this New York Times article about the US’s first (official, legal) safe consumption site, a description of a long-running unsanctioned safe injection site from the American Journal of Preventive Medicine, and this review article on safe consumption sites worldwide. We also talk about caring for medical workers who have substance use disorders. If you live in Pennsylvania and you are a healthcare professional with a substance use disorder, confidential help is available from the Physicians’ Health Program.

If you want your comments about this article included in a future episode, leave them in your CME quiz, email us at [email protected], talk to us on Twitter @AddicionMedJC, or even record a comment using the voice memo app on your phone and email it to us. Thank you for being part of the conversation.

At the conclusion of this presentation, the participant should be able to:
1. Summarize the main results from the featured article on the patient experience with depot versus sublingual buprenorphine
2. Analyze how the conclusions of the featured article affect their current treatment of opioid use disorder
3. Discuss the featured article with the hosts via CloudCME, email, or Twitter

Credits
Host: Sonya Del Tredici, MD
Host: John Keenan, MD
Music: Benjamin Kennedy
Audio Production: Angela Ohlfest
CME Coordinator: georgeanna ledgerwood, MLIS/LMT
Sponsor: WellSpan Health

1. Discuss the study design, results, and limitations of the research reviewed and how to apply those results to current practice
2. Analyze how the conclusions of the featured article affect their current treatment of opioid use disorder
3. Discuss the featured article and its impact on patient outcomes

AMA PRA Category 1 Credits™ (0.50 hours), Non-Physician Attendance (0.50 hours), Act 13 Patient Safety/Risk Management Credits (0.50 hours), Act 124 Opioid Continuing Education Qualified (0.50 hours)

Tuesday, March 1, 2022, 6:30 AM - Sunday, December 31, 2023, 7:00 AM

Accreditation Statement: WellSpan Health is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians. 

Credit Designation: WellSpan Health designates this Enduring Material activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All faculty participating in continuing medical education programs sponsored by WellSpan Health are expected to disclosure to the program audience whether they do or do not have any real or apparent conflict(s) of interest or other relationships related to the content of their presentation(s).

Mitigation of Relevant Financial Relationships

WellSpan Health CME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.